Levosimendan ohne Vorteil bei Sepsis

Die Behandlung eines septischen Schocks erfordert meist hoch dosierte Katecholamine. Hohe Katecholamindosen wiederum gehen mit Myokardschäden und peripheren Ischämien einher und tragen zu der schlechten Prognose bei. Ob der Kalzium-Sensitizer Levosimendan das Ausmaß der Organschädigung bei Sepsis vermindern kann, hat eine britische Gruppe untersucht.

• Literatur

• 1 Cecconi M. De BD. Antonelli M. et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 2014; 40: 1795-1815
• 2 Mebazaa A. Nieminen MS. Packer M. et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891
• 3 Orme RM. Perkins GD. McAuley DF. et al. An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. Trials 2014; 15: 199
• 4 Ponikowski P. Voors AA. Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200
• 5 Vincent JL. de Mendonça A. Cantraine F. et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26: 1793-1800